{
  "id": 16913866,
  "title": "Dassault Systèmes Q3 2026 slides: platform drives 5% growth, guidance raised",
  "url": "https://urgent.news/2026/10/28/dassault-systemes-q3-2026-slides-platform-drives-5-growth-guidance",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-28T14:53:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/dassault-systemes-q3-2026-slides-platform-drives-5-growth-guidance-raised-93CH-4979926"
  },
  "original_language": "en",
  "account": "On October 28, 2026, Dassault Systèmes released its Q3 2026 financial results, outperforming expectations with a 5% growth in revenue on a constant currency basis. The company also raised its full-year guidance, positioning 2026 as a foundation year for its AI-native transformation. CEO Pascal Daloz highlighted strong customer wins across industries and a significant reorganization of its life sciences business following the ArisGlobal acquisition. Despite the positive outlook, shares fell 2.31% to $24.12, near the stock's 52-week high of $24.98, as investors remained cautious. Revenue reached €1,552 million, with diluted earnings per share increasing by 8% to €0.32. Operating margin expanded by 150 basis points to 31.6%, indicating improved operational efficiency. Software revenue grew 5% year-over-year, with upfront license revenue surging 14% and recurring revenue advancing 3%. Subscription revenue, now accounting for 50% of total recurring revenue, increased 6%, marking a shift toward predictable revenue streams. The 3DEXPERIENCE platform, highlighted for its success, contributed 44% to eligible software revenue, up from 40% previously. Cloud revenue, representing 27% of year-to-date software revenue, grew 14%. Annual recurring revenue (ARR) reached €4.505 billion, up 6% year-over-year. Regional performance varied, with Asia leading growth at 12%, driven by China's expansion and aerospace high-tech sectors, while the Americas declined 3%, attributed to difficult year-over-year comparisons. In life sciences, the company announced a transformation led by Dr. Ashwini Zenooz, aimed at creating an AI-native platform for the entire drug development lifecycle. This strategic shift is supported by the ArisGlobal acquisition, which enables end-to-end integration of various stages in the pharmaceutical and biotech sectors.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}